La Jolla Pharmaceutical Stock Working Capital
LJPCDelisted Stock | USD 6.22 0.00 0.00% |
La Jolla Pharmaceutical fundamentals help investors to digest information that contributes to La Jolla's financial success or failures. It also enables traders to predict the movement of LJPC Stock. The fundamental analysis module provides a way to measure La Jolla's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to La Jolla stock.
LJPC |
LJPC Working Capital Analysis
La Jolla's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current La Jolla Working Capital | 79.5 M |
Most of La Jolla's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, La Jolla Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, La Jolla Pharmaceutical has a Working Capital of 79.5 M. This is 81.32% lower than that of the Healthcare sector and 85.24% lower than that of the Biotechnology industry. The working capital for all United States stocks is 94.62% higher than that of the company.
LJPC Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses La Jolla's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of La Jolla could also be used in its relative valuation, which is a method of valuing La Jolla by comparing valuation metrics of similar companies.La Jolla is currently under evaluation in working capital category among related companies.
LJPC Fundamentals
Return On Equity | 0.0544 | |||
Return On Asset | 1.64 | |||
Profit Margin | 10.08 % | |||
Operating Margin | 4.68 % | |||
Current Valuation | 242.85 M | |||
Shares Outstanding | 27.52 M | |||
Shares Owned By Insiders | 1.91 % | |||
Shares Owned By Institutions | 71.79 % | |||
Number Of Shares Shorted | 202.51 K | |||
Price To Earning | 38.88 X | |||
Price To Book | 30.11 X | |||
Price To Sales | 3.29 X | |||
Revenue | 52.01 M | |||
Gross Profit | 63.08 M | |||
EBITDA | 4.09 M | |||
Net Income | 5.24 M | |||
Cash And Equivalents | 44.56 M | |||
Cash Per Share | 1.74 X | |||
Total Debt | 124.8 M | |||
Debt To Equity | 7.16 % | |||
Current Ratio | 3.92 X | |||
Book Value Per Share | (3.36) X | |||
Cash Flow From Operations | 13.59 M | |||
Short Ratio | 0.46 X | |||
Earnings Per Share | (1.44) X | |||
Price To Earnings To Growth | 11.72 X | |||
Number Of Employees | 61 | |||
Beta | 1.97 | |||
Market Capitalization | 171.2 M | |||
Total Asset | 89.52 M | |||
Retained Earnings | (1.06 B) | |||
Working Capital | 79.5 M | |||
Current Asset | 86.74 M | |||
Current Liabilities | 7.24 M | |||
Z Score | -14.8 |
About La Jolla Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze La Jolla Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of La Jolla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of La Jolla Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. La Jolla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in LJPC Stock
If you are still planning to invest in La Jolla Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the La Jolla's history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |